SpyGlass Pharma

SGP · NASDAQ

$26.16+$1.56 (+6.34%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $24.60

About SGP

SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. The company is headquartered in Aliso Viejo, California and currently employs 65 full-time employees. The company went IPO on 2026-02-06. The firm is focused on developing and commercializing long-term, drug delivery solutions for patients suffering from ophthalmic diseases. Its lead product candidate is SpyGlass Drug Delivery Platform with bimatoprost, which is designed to deliver three years of bimotic anti-inflammatory therapy to targeted tissues in the eye.

Employees: 65
Headquarters: Aliso Viejo, California
Listed: Feb 6, 2026
Sector: Health Care
Industry: Pharmaceuticals
Website: spyglasspharma.com

Leadership

SpyGlass Pharma executives
Name	Title	Since	Age
Malik Kahook	—	2019	51
Patrick Mooney	—	2021	52
Jean-Frederic Viret	—	—	60
James Dennewill	—	—	45
Chetan Pujara	—	—	56
Ali Behbahani	—	—	49
Habib Dable	—	—	56
Michael Dybbs	—	—	51
Bilal Khan	—	—	45
Kirk Nielsen	—	—	52
Elizabeth O'Farrell	—	—	61
Geoff Pardo	—	—	54
Zach Scheiner	—	—	49

Similar companies

Companies in the same industry as SpyGlass Pharma

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.